To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy.

Bill 118 hr 4242, also known as the "Psychedelic Assisted Therapy Guidance Act," aims to direct the Secretary of Health and Human Services to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy. This bill specifically tasks the Commissioner of Food and Drugs with developing this guidance.

The purpose of this legislation is to provide a framework for researchers and healthcare professionals who are interested in exploring the potential benefits of psychedelic substances, such as psilocybin and MDMA, in therapeutic settings. These substances have shown promise in treating a variety of mental health conditions, including depression, PTSD, and anxiety.

By issuing guidance on conducting clinical trials for psychedelic assisted therapy, the Secretary of Health and Human Services hopes to facilitate research in this emerging field and ensure that studies are conducted in a safe and ethical manner. This guidance will outline best practices for designing and implementing clinical trials, as well as considerations for ensuring the safety and well-being of participants. Overall, Bill 118 hr 4242 represents a step towards expanding our understanding of the potential therapeutic benefits of psychedelic substances and providing guidance for researchers and healthcare professionals interested in exploring this promising area of treatment.